Clin Osteol 2006; 11(1): 3-4

Physiology and pathophysiology of phosphorus metabolism - still many questionsOriginal contributions

M. Bayer

Published: June 11, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bayer M. Physiology and pathophysiology of phosphorus metabolism - still many questions. Osteologický bulletin. 2006;11(1):3-4.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aschinberg LC, Solomon LM, Zeis PM, et al. Vitamin D-resistant rickets associa­ ted with epidermal nevus syndrome:demonstration of a phosphaturic substance in the dermal lesions. J Pediatr 1977;91:56-60. Go to original source...
    2. Kumar R. Tumor-induced Osteomalacia nad The Regulation of Phosphate Homeo­ stasis. Bone 2000;27:333-38. Go to original source...
    3. Silve C, Beck L. Is FGF23 the long sought after phosphaturic factor phosphatonin? Nephrol Dial Transplant 2002;17:958-61. Go to original source...
    4. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth fac­ tor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000;277:494-98. Go to original source...
    5. The ADHR Consorcium. Autosomal dominant hypophosphatemic rickets is asso­ ciated with mutation in FGF23. Nat Genet 2000;26:345 48. Go to original source...
    6. Shimada T, Mizutani S, Muto T, et al. Cloning and characterisation of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-05. Go to original source...
    7. Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002;143:3179-82. Go to original source...
    8. The HYP Consorcium. A gene (PEX) with homologies to endopeptidases is muta­ ted in patients with X-linked hypophosphatemic rickets. Nat Genet 1995;11:130-36. Go to original source...
    9. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of FGF23 demon­ strates an essential physiological role of FGF23 in phosphate and vitamin D meta­ bolism. J Clin Invest 2004;113:561-68. Go to original source...
    10. Rowe PS, Kumagai Y, Gutierez G, et al. MEPE has the properties of an osteoblas­ tic phosphatonin and minhibin. Bone 2004;34:303-19. Go to original source...
    11. Berndt T, Craig TA, Bowe AE, et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 2003;112:785-94. Go to original source...
    12. Wagner GF,Vozzolo BL, Jaworski E, et al. Human stanniocalcin inhibits renal phosphate excretion in the rat. J Bone Miner Res 1997;12:165-71. Go to original source...
    13. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate ho­ meostasis. Kidney Int 2004;65:1-14. Adresa: Doc. MUDr. Milan Bayer, CSc. Klinika dětského a dorostového lékařství 1. LF UK a VFN Ke Karlovu 2 128 08 Praha 2 Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.